Wall Street analysts expect Aquestive Therapeutics Inc (NASDAQ:AQST) to announce $10.19 million in sales for the current quarter, according to Zacks Investment Research. Two analysts have provided estimates for Aquestive Therapeutics’ earnings, with estimates ranging from $9.74 million to $10.63 million. Aquestive Therapeutics reported sales of $16.82 million during the same quarter last year, which indicates a negative year over year growth rate of 39.4%. The firm is scheduled to announce its next quarterly earnings results on Thursday, March 12th.
On average, analysts expect that Aquestive Therapeutics will report full-year sales of $46.38 million for the current fiscal year, with estimates ranging from $45.93 million to $46.82 million. For the next financial year, analysts forecast that the business will report sales of $64.11 million, with estimates ranging from $58.80 million to $69.41 million. Zacks Investment Research’s sales calculations are an average based on a survey of research firms that that provide coverage for Aquestive Therapeutics.
A number of brokerages have commented on AQST. Zacks Investment Research upgraded shares of Aquestive Therapeutics from a “hold” rating to a “buy” rating and set a $6.00 price target for the company in a research note on Monday, November 11th. Wedbush restated a “buy” rating and set a $37.00 price target on shares of Aquestive Therapeutics in a research note on Monday, December 2nd. HC Wainwright restated a “buy” rating and set a $14.00 price target (up previously from $12.00) on shares of Aquestive Therapeutics in a research note on Monday, December 2nd. Finally, ValuEngine upgraded shares of Aquestive Therapeutics from a “hold” rating to a “buy” rating in a research note on Monday. Six analysts have rated the stock with a buy rating, The stock presently has a consensus rating of “Buy” and a consensus price target of $18.40.
AQST stock traded down $0.26 during midday trading on Friday, reaching $7.75. 17,534 shares of the company’s stock traded hands, compared to its average volume of 1,138,559. The company has a market cap of $200.59 million, a price-to-earnings ratio of -2.76 and a beta of 2.70. The firm’s fifty day moving average price is $5.44 and its 200-day moving average price is $4.24. Aquestive Therapeutics has a 52 week low of $2.95 and a 52 week high of $10.00.
A number of institutional investors and hedge funds have recently bought and sold shares of the business. Squarepoint Ops LLC boosted its holdings in Aquestive Therapeutics by 6.8% during the 3rd quarter. Squarepoint Ops LLC now owns 40,777 shares of the company’s stock worth $130,000 after acquiring an additional 2,587 shares during the last quarter. California Public Employees Retirement System boosted its holdings in Aquestive Therapeutics by 5.8% during the 3rd quarter. California Public Employees Retirement System now owns 120,900 shares of the company’s stock worth $384,000 after acquiring an additional 6,600 shares during the last quarter. Meeder Asset Management Inc. boosted its holdings in Aquestive Therapeutics by 460.2% during the 3rd quarter. Meeder Asset Management Inc. now owns 8,129 shares of the company’s stock worth $26,000 after acquiring an additional 6,678 shares during the last quarter. Russell Investments Group Ltd. purchased a new position in Aquestive Therapeutics during the 3rd quarter worth $46,000. Finally, Morgan Stanley boosted its holdings in shares of Aquestive Therapeutics by 706.1% in the 2nd quarter. Morgan Stanley now owns 17,323 shares of the company’s stock worth $73,000 after buying an additional 15,174 shares during the last quarter. 62.69% of the stock is currently owned by hedge funds and other institutional investors.
About Aquestive Therapeutics
Aquestive Therapeutics, Inc, a specialty pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; and Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery in the United States and internationally.
Featured Story: What is a stock split?
Get a free copy of the Zacks research report on Aquestive Therapeutics (AQST)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aquestive Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquestive Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.